VERTEX PHARMACEUTICALS

(VRTX)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
258.59 USD   +1.23%
05/19Vertex Pharmaceuticals - Suketu Upadhyay Elected to Vertex Board of Directors
AQ
05/18VERTEX PHARMACEUTICALS INC / MA : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/18Suketu Upadhyay Elected to Vertex Board of Directors
BU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
254.17(c) 261.84(c) 252.35(c) 255.45(c) 258.59(c) Last
1 558 246 1 566 842 1 396 975 1 448 836 1 552 342 Volume
+3.02% +3.02% -3.62% +1.23% +1.23% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 8 585 M - -
Net income 2022 3 253 M - -
Net cash position 2022 10 823 M - -
P/E ratio 2022 20,5x
Yield 2022 -
Sales 2023 9 226 M - -
Net income 2023 3 558 M - -
Net cash position 2023 14 777 M - -
P/E ratio 2023 18,7x
Yield 2023 -
Capitalization 66 136 M 66 136 M -
EV / Sales 2022 6,44x
EV / Sales 2023 5,57x
Nbr of Employees 3 900
Free-Float 99,6%
More Financials
Company
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows: - income from sales of products (99.9%); - royalties and income from partnership, research, and development agreements (0.1%). Net sales are distributed... 
More about the company
Ratings of Vertex Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about VERTEX PHARMACEUTICALS
05/19Vertex Pharmaceuticals - Suketu Upadhyay Elected to Vertex Board of Directors
AQ
05/18VERTEX PHARMACEUTICALS INC / MA : Submission of Matters to a Vote of Security Holders (for..
AQ
05/18Suketu Upadhyay Elected to Vertex Board of Directors
BU
05/18Vertex Pharmaceuticals Incorporated Elects Suketu Upadhyay as Independent Director
CI
05/17Vertex Pharmaceuticals Pledges $50 Million to Health Equity
MT
05/17Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey L..
BU
05/17Vertex Pharmaceuticals Incorporated Announces Further Expansion in the Boston Seaport A..
CI
05/17Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants
BU
05/09UBS Adjusts Vertex Pharmaceuticals Price Target to $321 From $322, Maintains Buy Rating
MT
05/06VERTEX PHARMACEUTICALS INC / MA Management's Discussion and Analysis of Financial Cond..
AQ
05/06Goldman Sachs Adjusts Price Target for Vertex Pharmaceuticals to $368 From $329, Mainta..
MT
05/06Wells Fargo Adjusts Vertex Pharmaceuticals' Price Target to $305 From $300, Reiterates ..
MT
05/06Baird Downgrades Vertex Pharmaceuticals to Neutral From Outperform, Adjusts Price Targe..
MT
05/06RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $267 From $274, Keeps Sec..
MT
05/06Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $242 From $249, Maintai..
MT
More news
News in other languages on VERTEX PHARMACEUTICALS
05/18Vertex Pharmaceuticals Incorporated élit Suketu Upadhyay comme administrateur indépenda..
05/17Vertex Pharmaceuticals s'engage à verser 50 millions de dollars pour l'équité en santé
05/17Vertex Pharmaceuticals Incorporated annonce une nouvelle expansion dans le port maritim..
05/05Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED annonce des revenus de 2,1 mi..
05/05Hausse des résultats de Vertex Pharmaceuticals au premier trimestre ; réaffirmation des..
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 258,59 $
Average target price 294,18 $
Spread / Average Target 13,8%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS17.76%66 136
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612
GENMAB A/S-17.26%20 205